MAT as a Level of Care: Where Medication Fits in Treatment

Medication-assisted treatment is not a level of care in its own right. It is a part of other levels. It runs inside detox. It runs inside residential care, day programs and weekly outpatient visits. Federal guidance says medication for opioid use disorder should be integrated with both outpatient and residential treatment, and that people treated there should have access to it [3].

That distinction matters when you are choosing a program. The question is not “MAT or rehab”. It is which of the levels of care you need. Then it is whether the program at that level can prescribe. This page covers the medications and who can prescribe each one. It covers how the phases work and what the evidence says about counseling. And it covers how to ask a program the right question. It sits inside our wider guide to addiction treatment, alongside the full rundown on medication-assisted treatment.

What Medication-assisted Treatment Is, and What It Is Not

MAT means using an approved medication for a substance use disorder as part of treatment, usually alongside counseling and other support.

What it is not is a substitute addiction. That claim survives because two of the medications for opioid use disorder act on the same receptors as opioid drugs. The pharmacology is different. Methadone binds to and activates the same mu-opioid receptors as heroin and fentanyl, but activates them more slowly [2]. Buprenorphine activates those receptors to a lesser degree than methadone, and can also block other opioid drugs from attaching to them [2].

Nor is it a shortcut that replaces the rest of treatment. Federal guidance describes medication as something patients should have access to in many settings [3]. That includes general medical care, office-based treatment and specialty addiction programs. It is not a stand-alone service.

And it is not only for opioids. Medications exist for alcohol use disorder too, and that half of the field is chronically under-discussed.

The FDA position on the opioid medications is straightforward: all three have been demonstrated to be safe and effective [1].

MAT Inside Residential Care vs MAT as Outpatient Care

The same medication does different work depending on where you are standing.

Inside residential and inpatient care, medication is started and adjusted under daily observation. Staff see the response. Other conditions are managed at the same time. The catch is that residential care ends. So the plan has to cover life on the outside before discharge, not after it.

Inside outpatient care, medication is the spine of the treatment rather than one element among many. Visits are periodic. Federal guidance describes outpatient care as including regular office or telehealth visits for counseling, medication support, or both [5]. Between visits, you manage it yourself.

Inside medical detox, medication does a different job again: managing withdrawal safely, and for opioid use disorder, deciding whether to transition straight onto ongoing medication rather than stopping.

The practical implication is the one people miss. Ask a residential program what the medication handover looks like at discharge. Ask an outpatient program what happens if you need more support than visits provide. The failure point is almost always a transition, not a level.

The Three FDA-approved Medications for Opioid Use Disorder

There are three medications approved by the FDA for the treatment of opioid use disorder: buprenorphine, methadone and naltrexone [1]. They differ in how they act and, for the purposes of this page, in where you can get them. Our guide to medication-assisted treatment gives the full rundown on each; what follows is only the part that decides which level of care can serve you.

Methadone activates mu-opioid receptors more slowly than heroin or fentanyl do [2]. For opioid use disorder it is only available from approved opioid treatment programs [2]. That is a structural constraint rather than a clinical one: it shapes where you can live and how often you travel.

Buprenorphine activates the same receptors to a lesser degree and can block other opioid drugs from attaching [2]. It can be prescribed by many doctors, nurse practitioners and physician assistants, with no need to visit a special clinic [2]. That makes it the most geographically available of the three.

Naltrexone blocks opioid receptors so that opioid drugs no longer produce pleasure, and any health care provider can prescribe it [2]. Because it is a blocker, timing matters. Treatment is typically started after a person has completely stopped taking other opioid drugs; otherwise the medication may cause withdrawal symptoms [2]. In practice that usually means stopping opioids for 7 to 10 days first, though research suggests faster approaches can also work [2].

Which one fits is a clinical decision that depends on history, other conditions and what is realistic where you live. It is not a decision to make from a web page.

If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.

Medications for Alcohol Use Disorder

The alcohol side gets far less attention and is worth knowing about. The National Institute on Drug Abuse lists naltrexone, disulfiram and acamprosate among the common medications used to treat alcohol addiction and withdrawal [4].

They do three different things in outline. Naltrexone blocks the pleasurable feelings of intoxication, which may help someone cut back or stop drinking [7]. Acamprosate helps reduce cravings and dependence on alcohol in people who have recently stopped [7]. Disulfiram causes a very bad reaction if someone drinks, so it works as a deterrent rather than on craving, and it is used only after a person has already stopped [7]. Our guide to medication-assisted treatment covers all three at greater length.

None of these is a treatment on its own, and none is prescribed just because someone asks for it at intake. Liver function, other medications, pregnancy and mental health history all bear on the choice, which is why the prescriber needs the full picture gathered at the rehab intake process.

The reason to raise it here is simple. People arrive at treatment for alcohol assuming medication is an opioid-only option. It is not, and asking whether it is appropriate is a reasonable question to put to any program.

Counseling Requirements and What the Evidence Says

This is where a real shift has happened, and where a lot of older writing is out of date.

Federal guidance now frames counseling as something that should be available. It does not frame it as the price of getting medication. It says patients should have access to mental health services, medical care, addiction counseling and recovery support [3]. It also notes that many patients taking medication benefit from counseling as part of treatment [3].

Read that carefully. “Should have access to” and “many benefit from” are not the same as “must complete first”. The guidance’s own framing is patient-centered care, which it describes as empowering patients with information that helps them make better treatment decisions with the professionals involved in their care [3]. A blanket counseling rule is the opposite of that, and the guidance does not impose one.

So a program that will not prescribe unless you attend a set number of groups is making a local choice. It is not following a federal rule. That may still be the right call for one person. It is worth knowing which it is.

None of this argues against counseling. The range of therapies used in addiction treatment does work medication cannot. It rebuilds routines. It helps repair relationships, and it works on the places where use restarted. The point is only that access to medication should not be used as leverage.

Induction, Stabilization and Maintenance

Medication treatment runs in phases, and knowing the shape helps you judge whether a program is doing it properly. Our overview of what the rehab process is like sets the same expectations for the rest of treatment.

Induction is the start. The prescriber begins the medication and watches how the person responds. For naltrexone this is the phase where the 7 to 10 day opioid-free gap matters [2]. For the other two, the work is finding the point where withdrawal and craving settle without oversedation. This page will not give you numbers for any of that. The answer depends on the person, and it belongs to the prescriber.

Stabilization follows. Changes become less frequent. The rest of treatment was on hold while the medicine settled. Now it can take proper hold.

Maintenance is the long phase, and it is genuinely long. Federal guidance notes that many people with opioid use disorder benefit from treatment with medication for varying lengths of time, including lifelong treatment [3].

That last phrase surprises people. It should not. Federal guidance also treats substance use disorder as a condition where long-term or multiple episodes of treatment are often needed [5]. Our guide to how long rehab takes makes the same point across levels of care.

Stopping MAT: When, How and With Whom

Stopping is a clinical decision made with the prescriber, and the timing question has no general answer.

What federal guidance does say is that the duration varies, up to and including lifelong treatment [3]. So “when can I come off” is the wrong opening question. “What would we want to see before we considered changing this” is the better one.

The how is not something to attempt independently. Any change to an opioid use disorder medication belongs with the prescriber who started it, and that includes any taper. That is this site’s position rather than a quotation, and two findings from NIDA sit behind it [2] [4].

The first is a comparison, not a property of the drugs on their own: people with opioid use disorder who are treated with methadone or buprenorphine are less likely to die or to have an overdose than people who do not receive treatment [2]. The second is that tolerance falls during any stretch without opioids, so if a person uses as much as they did before quitting, they can easily overdose because their body is no longer adapted to that level of exposure [4]. Stopping abruptly, or stopping because a program ended rather than because a clinician judged it right, removes the first protection and walks into the second.

If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.

The with whom is where things most often go wrong. You may move from residential care to outpatient rehab. You may move between states. Either way, confirm who holds the prescription before the handover, not after. Get a name, a practice and a first appointment date. A two-week gap between prescribers is a risk, not a paperwork detail.

Which Campuses Offer MAT

Two campuses card medically-assisted treatment on their own Levels of Care lists. The Recovery Village Ridgefield in Ridgefield, Washington cards it alongside medical detox, inpatient treatment, a partial hospitalization program, an intensive outpatient program and a dual diagnosis track. The Recovery Village Kansas City in Raytown, Missouri cards it alongside medical detox, residential rehab for substance use, residential rehab for mental health, an intensive outpatient program, a dual diagnosis track and aftercare planning.

That is what those two campuses publish, and it is worth being precise about what it means. A card list states what a campus publishes rather than the whole of what a prescriber can do there. Prescribing varies by campus, by state rules and by the medicine. Methadone in particular is restricted to approved opioid treatment programs wherever you are [2].

So the reliable route is to ask during the assessment call. Ask about a named medicine rather than about “MAT”. Whether this campus can start buprenorphine. Whether it can continue a prescription you already hold. What happens to it at discharge. Our directory of treatment facilities lists the levels of care each location runs, and our treatment center profiles group the campuses by state, and our guide to the admissions process covers when to raise it. The admissions team can answer the prescribing question for a named site. If a program cannot answer it plainly, that tells you something about the program.

Frequently Asked Questions

Sources

1. US Food and Drug Administration. Information about Medications for Opioid Use Disorder (MOUD). https://www.fda.gov/drugs/food-and-drug-administration-overdose-prevention-framework/information-about-medications-opioid-use-disorder-moud
2. National Institute on Drug Abuse. Medications for Opioid Use Disorder. National Institutes of Health. https://nida.nih.gov/research-topics/medications-opioid-use-disorder
3. Substance Abuse and Mental Health Services Administration. (2018). Medications for Opioid Use Disorder, Executive Summary. Treatment Improvement Protocol (TIP) Series, No. 63. NCBI Bookshelf, National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK535275/
4. National Institute on Drug Abuse. Treatment and Recovery. Drugs, Brains, and Behavior: The Science of Addiction. National Institutes of Health. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
5. National Institute on Drug Abuse. Treatment. National Institutes of Health. https://nida.nih.gov/research-topics/treatment
6. Centers for Medicare & Medicaid Services. The Mental Health Parity and Addiction Equity Act (MHPAEA). https://www.cms.gov/marketplace/private-health-insurance/mental-health-parity-addiction-equity
7. MedlinePlus. Alcohol use disorder. Medical Encyclopedia, National Library of Medicine, National Institutes of Health. https://medlineplus.gov/ency/article/000944.htm

This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.

Author

Kevin Wandler, MD

Chief Medical Officer, The Recovery Village